blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3683317

EP3683317 - ANTI-HUMAN CD52 IMMUNOGLOBULINS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.03.2024
Database last updated on 14.03.2026
FormerExamination is in progress
Status updated on  05.05.2023
FormerRequest for examination was made
Status updated on  03.04.2021
FormerThe application has been published
Status updated on  19.06.2020
Most recent event   Tooltip01.03.2024Application deemed to be withdrawnpublished on 03.04.2024  [2024/14]
Applicant(s)For all designated states
Genzyme Corporation
50 Binney Street
Cambridge, MA 02142 / US
[2020/30]
Inventor(s)01 / ROBERTS, Bruce L.
108 Pine Hill Road
Southborough, MA 01772 / US
02 / SHANKARA, Srinivas
17 Sheryl Drive
Shrewsbury, MA 01545 / US
03 / BRONDYK, William Harold
52 Darby Drive
Mansfield, MA 02048 / US
04 / SIDERS, William M.
618 Lisa Lane
Franklin, MA 02038 / US
 [2020/30]
Representative(s)Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2020/30]Miller, David James
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Application number, filing date19214547.213.05.2010
[2020/30]
Priority number, dateUS200917783709P13.05.2009         Original published format: US 17783709 P
[2020/30]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3683317
Date:22.07.2020
Language:EN
[2020/30]
Type: A3 Search report 
No.:EP3683317
Date:30.09.2020
Language:EN
[2020/40]
Search report(s)(Supplementary) European search report - dispatched on:EP01.09.2020
ClassificationIPC:C12P21/08, A61K39/00, A61K39/395, C07K16/28
[2020/30]
CPC:
C07K16/2893 (EP,KR,RU,US); A61K39/395 (KR); A61P19/02 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/04 (EP); A61P37/06 (EP); A61P9/00 (EP);
C12N15/63 (KR); A61K2039/505 (EP,KR,US); C07K2317/24 (EP,KR,US);
C07K2317/34 (EP,US); C07K2317/52 (EP,KR,US); C07K2317/565 (KR,US);
C07K2317/64 (KR,US); C07K2317/732 (EP,KR,US); C07K2317/734 (EP,KR,US);
C07K2317/76 (US); C07K2317/94 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2021/18]
Former [2020/30]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesBA30.03.2021
ME30.03.2021
RS30.03.2021
TitleGerman:ANTI-HUMAN-CD52-IMMUNGLOBULINE[2020/30]
English:ANTI-HUMAN CD52 IMMUNOGLOBULINS[2020/30]
French:IMMUNOGLOBULINES ANTI-CD52 HUMAIN[2020/30]
Examination procedure30.03.2021Amendment by applicant (claims and/or description)
30.03.2021Examination requested  [2021/18]
30.03.2021Date on which the examining division has become responsible
04.05.2023Despatch of a communication from the examining division (Time limit: M06)
15.11.2023Application deemed to be withdrawn, date of legal effect  [2024/14]
05.12.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/14]
Parent application(s)   TooltipEP10775530.8  / EP2429582
EP15191351.4  / EP2998405
Fees paidRenewal fee
09.12.2019Renewal fee patent year 03
09.12.2019Renewal fee patent year 04
09.12.2019Renewal fee patent year 05
09.12.2019Renewal fee patent year 06
09.12.2019Renewal fee patent year 07
09.12.2019Renewal fee patent year 08
09.12.2019Renewal fee patent year 09
09.12.2019Renewal fee patent year 10
31.03.2020Renewal fee patent year 11
12.05.2021Renewal fee patent year 12
20.03.2022Renewal fee patent year 13
14.03.2023Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]   JOHN G. GRIBBEN ET AL: "Rediscovering alemtuzumab: current and emerging therapeutic roles", BRITISH JOURNAL OF HAEMATOLOGY, vol. 144, no. 6, 1 March 2009 (2009-03-01), pages 818 - 831, XP055048034, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2008.07557.x

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2008.07557.x
 [I]   HIRST C L ET AL: "Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis", JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DA, vol. 255, no. 2, 20 February 2008 (2008-02-20), pages 231 - 238, XP019589775, ISSN: 1432-1459
 [I]   J.D. ISAACS ET AL: "Humanised monoclonal antibody therapy for rheumatoid arthritis", THE LANCET, vol. 340, no. 8822, 1 September 1992 (1992-09-01), pages 748 - 752, XP055048146, ISSN: 0140-6736, DOI: 10.1016/0140-6736(92)92294-P

DOI:   http://dx.doi.org/10.1016/0140-6736(92)92294-P
 [I]   HALE G: "Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 1, no. 3, 1 December 1995 (1995-12-01), pages 175 - 187, XP004052720, ISSN: 1380-2933, DOI: 10.1016/1380-2933(95)00017-8

DOI:   http://dx.doi.org/10.1016/1380-2933(95)00017-8
by applicantUS17783709
 US9209665
 WO9852976
 US4816567
 EP0125023
 US4816397
 EP0120694
 WO8601533
 EP0194276
 US5225539
 EP0239400
 EP0519596
 US4946778
 US5476786
 US7264806
 GB2209757
 WO8907142
 WO9429351
 US5530101
 WO9404679
 US6407213
 WO9806248
 WO03048731
 US6331415
 US7662623
 WO9426087
 WO9203918
 US2006251658
 WO0166754
 US5208020
 US6333410
 WO0138318
 US4970198
 US5264586
 US5550246
 US5712374
 US5714586
 US5070092
 US5187186
 US5641780
 US4923990
 US5101038
 US5475092
 US5585499
 US5846545
 WO2008031626
   HALE ET AL., J BIOL REGUL HOMEOST AGENTS, vol. 15, 2001, pages 386 - 391
   HUH ET AL., BLOOD, vol. 92, 1998
   EISNER ET AL., BLOOD, vol. 88, 1996, pages 4684 - 4693
   GILLEECE ET AL., BLOOD, vol. 82, 1993, pages 807 - 812
   RODIG ET AL., CLIN CANCER RES, vol. 12, 2006, pages 7174 - 7179
   GINALDI ET AL., LEUK RES, vol. 22, 1998, pages 185 - 191
   DOMAGALA ET AL., MED SCI MONIT, vol. 7, 2001, pages 325 - 331
   ROWAN ET AL., INT IMMUNOL, vol. 7, 1995, pages 69 - 77
   MASUYAMA ET AL., JEXP MED, vol. 189, 1999, pages 979 - 989
   WATANABE ET AL., CLIN IMMUNOL, vol. 120, 2006, pages 247 - 259
   TREUMANN, A. ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 6088 - 6099
   NATURE REVIEWS DRUG DISCOVERY, vol. 6, 2007, pages 75 - 92
   RHEUMATOLOGY, vol. 39, 2000, pages 229 - 237
   RHEUMATOLOGY, vol. 42, 2003, pages 1539 - 1544
   VIVAS, S. ET AL., N. ENGI. J. MED., vol. 354, no. 23, 2006, pages 2514 - 2515
   AGARWAL ET AL., TRANSPLANT IMMUNOL., vol. 20, 2008, pages 6 - 11
   BURT ET AL., THE LANCET, 30 January 2009 (2009-01-30)
   LUNDIN, J. ET AL., BLOOD, vol. 101, 2003, pages 4267 - 4272
   RODIG, SJ. ET AL., CLINICAL CANCER RESEARCH, vol. 12, no. 23, 2006, pages 7174 - 7179
   RODIG, SJ ET AL., CLIN. CANCER RES., vol. 12, no. 23, 2006, pages 7174 - 717179
   HEDERER ET AL., INTERNATIONAL IMMUNOLOGY, vol. 12, 2000, pages 505 - 616
   WATANABE ET AL., CLINICAL IMMUNOLOGY, vol. 120, 2006, pages 247 - 259
   HALE G ET AL.: "The CAMPATH-1 antigen (CD52", TISSUE ANTIGENS, vol. 35, 1990, pages 178 - 327
   LIM, J. HEMATOLOGY & ONCOLOGY, vol. 1, 2008, pages 19
   KETTLEBOROUGH, C. A. ET AL., PROTEIN ENGINEERING, vol. 4, 1991, pages 773 - 783
   CHOTHIALESK: "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
   NISONOFF, A.: "Introduction to Molecular Immunology", 1984, SINAUER ASSOCIATES, INC., pages: 45 - 65
   NATURE BIOTECHNOLOGY, vol. 22, no. 9, 2004, pages 1161 - 1165
   PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
   PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
   ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
   PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
   GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
   BIRD, R.E. ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
   DAUGHERTY, B.L. ET AL., NUCLEIC ACIDS RES., vol. 19, no. 9, 1991, pages 2471 - 2476
   JIA ET AL., J. IMMUNOL. METHODS, vol. 288, 2004, pages 91 - 98
   KAMMAN, M. ET AL., NUCL. ACIDS RES., vol. 17, 1989, pages 5404
   SATO, K. ET AL., CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
   KOLBINGER, F., PROTEIN ENGINEERING, vol. 8, 1993, pages 971 - 980
   LEWIS, AP.J.S. CROWE, GENE, vol. 101, 1991, pages 297 - 302
   URLAUB, G.CHASIN, LA., PROC. NATI. ACAC. SCI. USA, vol. 77, no. 7, 1980, pages 4216 - 4220
   DAILEY, L. ET AL., J. VIROL., vol. 54, 1985, pages 739 - 749
   PEAR, W. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 8392 - 8396
   "Current Protocols in Molecular Biology", vol. 2, 1991, GREENE PUBLISHING ASSOCIATES AND JOHN WILEY & SONS INC., pages: 16.4.1 - 16.7.8
   OSBURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68
   LUBLIN, NEUROLOGY, vol. 46, no. 4, 1996, pages 907 - 11
   CHING ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10006 - 10010
   BRODER ET AL., ANN. INT. MED., vol. 113, 1990, pages 604 - 618
   LOREAU ET AL., FEBS LETTERS, vol. 274, 1990, pages 53 - 56
   KONTERMANN, R.E., METHODS, vol. 34, 2004, pages 163 - 170
   REIFF, A., HEMATOLOGY, vol. 10, no. 2, 2005, pages 79 - 93
   PULASKI ET AL., J. TRANSLATIONAL MED., vol. 7, 2009, pages 49
   SPORTES ET AL., CYTOKINE THERAPIES: ANN. N. Y. ACAD. SCI., vol. 1182, 2009, pages 28 - 38
   HU ET AL., IMMUNOLOGY, vol. 128, 2009, pages 260 - 270
   BACH ET AL., IMMUNOL., vol. 3, 2003, pages 189 - 98
   BARRAT ET AL., J. EXP. MED., vol. 195, 2002, pages 603 - 616
   GREGORI ET AL., J IMMUNOL., vol. 167, 2001, pages 1945 - 1953
   BATTAGLIA ET AL., BLOOD, vol. 105, 2005, pages 4743 - 4748
   BATTAGLIA ET AL., J. IMMUNOL., vol. 177, 2006, pages 8338 - 8347
   MANDL ET AL.: "Systemic Lupus Erythematosus", 2004, ELSEVIER ACADEMIC PRESS, article "Monitoring patients with systemic lupus erythematosus", pages: 619 - 631
   WALSH, ANN RHEUM DIS, vol. 67, 2008, pages 1322 - 1327
   "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING CO.
   RAWSTROM ET AL., BR. J. HEAM., vol. 107, 1999, pages 148 - 153
   GILLILAND LK ET AL., JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 3663 - 3671
   TOMLINSON, IM ET AL., EMBO J., vol. 14, no. 18, 1995, pages 4628 - 4638
   COOK, GP. ET AL., NATURE GENETICS, vol. 7, 1994, pages 162 - 168
   "Alemtuzumab vs. interferon Beta-la in early multiple sclerosis", NENGL J MED, vol. 359, 2008, pages 1786 - 1801
   KIM ET AL.: "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn", EUR. J. IMMUNOL., vol. 29, 1999, pages 2819 - 2825, XP002300286, DOI: 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6

DOI:   http://dx.doi.org/10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6
   KENANOVA ET AL.: "Tailoring the Pharmacokinetics and Positron Emission Tomography Imaging Properties of Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments", CANCER. RES., vol. 65, no. 2, 2005, pages 622 - 631, XP009089506
   HALE G: "Synthetic peptide mimotype of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein", IMMUNOTECHNOLOGY, vol. 1, 1995, pages 175 - 187, XP004052720, DOI: 10.1016/1380-2933(95)00017-8

DOI:   http://dx.doi.org/10.1016/1380-2933(95)00017-8
   ALEXANDER J ET AL.: "Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides", IMMUNITY, vol. 1, 1994, pages 751 - 761, XP000673954, DOI: 10.1016/S1074-7613(94)80017-0

DOI:   http://dx.doi.org/10.1016/S1074-7613(94)80017-0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.